Global Peptide-based Injectable Drugs Supply, Demand and Key Producers, 2023-2029
The global Peptide-based Injectable Drugs market size is expected to reach $ 43880 million by 2029, rising at a market growth of 4.1% CAGR during the forecast period (2023-2029).
Injectable peptide drugs offer several advantages over other administration routes, such as oral or topical delivery. When injected, peptides can bypass the gastrointestinal tract, avoiding issues such as degradation by stomach acid or poor absorption. Additionally, injections can provide a more rapid and direct delivery of the drug into the bloodstream, allowing for faster onset of action.
Peptide-based injectable drugs refer to medications that contain peptides as their active ingredients and are administered via injection. Peptides are short chains of amino acids, which are the building blocks of proteins. They play crucial roles in various biological processes and can be used therapeutically to target specific cellular pathways or receptors.
This report studies the global Peptide-based Injectable Drugs demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide-based Injectable Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide-based Injectable Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide-based Injectable Drugs total market, 2018-2029, (USD Million)
Global Peptide-based Injectable Drugs total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Peptide-based Injectable Drugs total market, key domestic companies and share, (USD Million)
Global Peptide-based Injectable Drugs revenue by player and market share 2018-2023, (USD Million)
Global Peptide-based Injectable Drugs total market by Type, CAGR, 2018-2029, (USD Million)
Global Peptide-based Injectable Drugs total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Peptide-based Injectable Drugs market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie and Ipsen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peptide-based Injectable Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Peptide-based Injectable Drugs Market, By Region:
1. How big is the global Peptide-based Injectable Drugs market?
2. What is the demand of the global Peptide-based Injectable Drugs market?
3. What is the year over year growth of the global Peptide-based Injectable Drugs market?
4. What is the total value of the global Peptide-based Injectable Drugs market?
5. Who are the major players in the global Peptide-based Injectable Drugs market?
6. What are the growth factors driving the market demand?
Injectable peptide drugs offer several advantages over other administration routes, such as oral or topical delivery. When injected, peptides can bypass the gastrointestinal tract, avoiding issues such as degradation by stomach acid or poor absorption. Additionally, injections can provide a more rapid and direct delivery of the drug into the bloodstream, allowing for faster onset of action.
Peptide-based injectable drugs refer to medications that contain peptides as their active ingredients and are administered via injection. Peptides are short chains of amino acids, which are the building blocks of proteins. They play crucial roles in various biological processes and can be used therapeutically to target specific cellular pathways or receptors.
This report studies the global Peptide-based Injectable Drugs demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide-based Injectable Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide-based Injectable Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide-based Injectable Drugs total market, 2018-2029, (USD Million)
Global Peptide-based Injectable Drugs total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Peptide-based Injectable Drugs total market, key domestic companies and share, (USD Million)
Global Peptide-based Injectable Drugs revenue by player and market share 2018-2023, (USD Million)
Global Peptide-based Injectable Drugs total market by Type, CAGR, 2018-2029, (USD Million)
Global Peptide-based Injectable Drugs total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Peptide-based Injectable Drugs market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie and Ipsen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peptide-based Injectable Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Peptide-based Injectable Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Brand
- Generic Drug
- Cancer
- Metabolic Disorders
- Central Nervous System
- Other
- Sanofi
- Teva
- Novo Nordisk
- Takeda
- Eli Lilly
- AstraZeneca
- Novartis
- AbbVie
- Ipsen
- Ferring
- Merck
- The Medicines
- Roche
- J & J
1. How big is the global Peptide-based Injectable Drugs market?
2. What is the demand of the global Peptide-based Injectable Drugs market?
3. What is the year over year growth of the global Peptide-based Injectable Drugs market?
4. What is the total value of the global Peptide-based Injectable Drugs market?
5. Who are the major players in the global Peptide-based Injectable Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Peptide-based Injectable Drugs Introduction
1.2 World Peptide-based Injectable Drugs Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Peptide-based Injectable Drugs Total Market by Region (by Headquarter Location)
1.3.1 World Peptide-based Injectable Drugs Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.3 China Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.4 Europe Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.5 Japan Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.6 South Korea Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.7 ASEAN Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.8 India Peptide-based Injectable Drugs Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide-based Injectable Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Peptide-based Injectable Drugs Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.2 World Peptide-based Injectable Drugs Consumption Value by Region
2.2.1 World Peptide-based Injectable Drugs Consumption Value by Region (2018-2023)
2.2.2 World Peptide-based Injectable Drugs Consumption Value Forecast by Region (2024-2029)
2.3 United States Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.4 China Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.5 Europe Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.6 Japan Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.7 South Korea Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.8 ASEAN Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.9 India Peptide-based Injectable Drugs Consumption Value (2018-2029)
3 WORLD PEPTIDE-BASED INJECTABLE DRUGS COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide-based Injectable Drugs Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide-based Injectable Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide-based Injectable Drugs in 2022
3.2.3 Global Concentration Ratios (CR8) for Peptide-based Injectable Drugs in 2022
3.3 Peptide-based Injectable Drugs Company Evaluation Quadrant
3.4 Peptide-based Injectable Drugs Market: Overall Company Footprint Analysis
3.4.1 Peptide-based Injectable Drugs Market: Region Footprint
3.4.2 Peptide-based Injectable Drugs Market: Company Product Type Footprint
3.4.3 Peptide-based Injectable Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide-based Injectable Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide-based Injectable Drugs Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Peptide-based Injectable Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Peptide-based Injectable Drugs Consumption Value Comparison
4.2.1 United States VS China: Peptide-based Injectable Drugs Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Peptide-based Injectable Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Peptide-based Injectable Drugs Companies and Market Share, 2018-2023
4.3.1 United States Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023)
4.4 China Based Companies Peptide-based Injectable Drugs Revenue and Market Share, 2018-2023
4.4.1 China Based Peptide-based Injectable Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023)
4.5 Rest of World Based Peptide-based Injectable Drugs Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Peptide-based Injectable Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Generic Drug
5.3 Market Segment by Type
5.3.1 World Peptide-based Injectable Drugs Market Size by Type (2018-2023)
5.3.2 World Peptide-based Injectable Drugs Market Size by Type (2024-2029)
5.3.3 World Peptide-based Injectable Drugs Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peptide-based Injectable Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Cancer
6.2.2 Metabolic Disorders
6.2.3 Central Nervous System
6.2.4 Other
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World Peptide-based Injectable Drugs Market Size by Application (2018-2023)
6.3.2 World Peptide-based Injectable Drugs Market Size by Application (2024-2029)
6.3.3 World Peptide-based Injectable Drugs Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Sanofi
7.1.1 Sanofi Details
7.1.2 Sanofi Major Business
7.1.3 Sanofi Peptide-based Injectable Drugs Product and Services
7.1.4 Sanofi Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Sanofi Recent Developments/Updates
7.1.6 Sanofi Competitive Strengths & Weaknesses
7.2 Teva
7.2.1 Teva Details
7.2.2 Teva Major Business
7.2.3 Teva Peptide-based Injectable Drugs Product and Services
7.2.4 Teva Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Teva Recent Developments/Updates
7.2.6 Teva Competitive Strengths & Weaknesses
7.3 Novo Nordisk
7.3.1 Novo Nordisk Details
7.3.2 Novo Nordisk Major Business
7.3.3 Novo Nordisk Peptide-based Injectable Drugs Product and Services
7.3.4 Novo Nordisk Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Novo Nordisk Recent Developments/Updates
7.3.6 Novo Nordisk Competitive Strengths & Weaknesses
7.4 Takeda
7.4.1 Takeda Details
7.4.2 Takeda Major Business
7.4.3 Takeda Peptide-based Injectable Drugs Product and Services
7.4.4 Takeda Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Takeda Recent Developments/Updates
7.4.6 Takeda Competitive Strengths & Weaknesses
7.5 Eli Lilly
7.5.1 Eli Lilly Details
7.5.2 Eli Lilly Major Business
7.5.3 Eli Lilly Peptide-based Injectable Drugs Product and Services
7.5.4 Eli Lilly Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Eli Lilly Recent Developments/Updates
7.5.6 Eli Lilly Competitive Strengths & Weaknesses
7.6 AstraZeneca
7.6.1 AstraZeneca Details
7.6.2 AstraZeneca Major Business
7.6.3 AstraZeneca Peptide-based Injectable Drugs Product and Services
7.6.4 AstraZeneca Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 AstraZeneca Recent Developments/Updates
7.6.6 AstraZeneca Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Peptide-based Injectable Drugs Product and Services
7.7.4 Novartis Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 AbbVie
7.8.1 AbbVie Details
7.8.2 AbbVie Major Business
7.8.3 AbbVie Peptide-based Injectable Drugs Product and Services
7.8.4 AbbVie Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 AbbVie Recent Developments/Updates
7.8.6 AbbVie Competitive Strengths & Weaknesses
7.9 Ipsen
7.9.1 Ipsen Details
7.9.2 Ipsen Major Business
7.9.3 Ipsen Peptide-based Injectable Drugs Product and Services
7.9.4 Ipsen Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Ipsen Recent Developments/Updates
7.9.6 Ipsen Competitive Strengths & Weaknesses
7.10 Ferring
7.10.1 Ferring Details
7.10.2 Ferring Major Business
7.10.3 Ferring Peptide-based Injectable Drugs Product and Services
7.10.4 Ferring Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Ferring Recent Developments/Updates
7.10.6 Ferring Competitive Strengths & Weaknesses
7.11 Merck
7.11.1 Merck Details
7.11.2 Merck Major Business
7.11.3 Merck Peptide-based Injectable Drugs Product and Services
7.11.4 Merck Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Merck Recent Developments/Updates
7.11.6 Merck Competitive Strengths & Weaknesses
7.12 The Medicines
7.12.1 The Medicines Details
7.12.2 The Medicines Major Business
7.12.3 The Medicines Peptide-based Injectable Drugs Product and Services
7.12.4 The Medicines Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 The Medicines Recent Developments/Updates
7.12.6 The Medicines Competitive Strengths & Weaknesses
7.13 Roche
7.13.1 Roche Details
7.13.2 Roche Major Business
7.13.3 Roche Peptide-based Injectable Drugs Product and Services
7.13.4 Roche Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Roche Recent Developments/Updates
7.13.6 Roche Competitive Strengths & Weaknesses
7.14 J & J
7.14.1 J & J Details
7.14.2 J & J Major Business
7.14.3 J & J Peptide-based Injectable Drugs Product and Services
7.14.4 J & J Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 J & J Recent Developments/Updates
7.14.6 J & J Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peptide-based Injectable Drugs Industry Chain
8.2 Peptide-based Injectable Drugs Upstream Analysis
8.3 Peptide-based Injectable Drugs Midstream Analysis
8.4 Peptide-based Injectable Drugs Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Peptide-based Injectable Drugs Introduction
1.2 World Peptide-based Injectable Drugs Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Peptide-based Injectable Drugs Total Market by Region (by Headquarter Location)
1.3.1 World Peptide-based Injectable Drugs Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.3 China Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.4 Europe Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.5 Japan Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.6 South Korea Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.7 ASEAN Peptide-based Injectable Drugs Market Size (2018-2029)
1.3.8 India Peptide-based Injectable Drugs Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide-based Injectable Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Peptide-based Injectable Drugs Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.2 World Peptide-based Injectable Drugs Consumption Value by Region
2.2.1 World Peptide-based Injectable Drugs Consumption Value by Region (2018-2023)
2.2.2 World Peptide-based Injectable Drugs Consumption Value Forecast by Region (2024-2029)
2.3 United States Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.4 China Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.5 Europe Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.6 Japan Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.7 South Korea Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.8 ASEAN Peptide-based Injectable Drugs Consumption Value (2018-2029)
2.9 India Peptide-based Injectable Drugs Consumption Value (2018-2029)
3 WORLD PEPTIDE-BASED INJECTABLE DRUGS COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide-based Injectable Drugs Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide-based Injectable Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide-based Injectable Drugs in 2022
3.2.3 Global Concentration Ratios (CR8) for Peptide-based Injectable Drugs in 2022
3.3 Peptide-based Injectable Drugs Company Evaluation Quadrant
3.4 Peptide-based Injectable Drugs Market: Overall Company Footprint Analysis
3.4.1 Peptide-based Injectable Drugs Market: Region Footprint
3.4.2 Peptide-based Injectable Drugs Market: Company Product Type Footprint
3.4.3 Peptide-based Injectable Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide-based Injectable Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide-based Injectable Drugs Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Peptide-based Injectable Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Peptide-based Injectable Drugs Consumption Value Comparison
4.2.1 United States VS China: Peptide-based Injectable Drugs Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Peptide-based Injectable Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Peptide-based Injectable Drugs Companies and Market Share, 2018-2023
4.3.1 United States Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023)
4.4 China Based Companies Peptide-based Injectable Drugs Revenue and Market Share, 2018-2023
4.4.1 China Based Peptide-based Injectable Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023)
4.5 Rest of World Based Peptide-based Injectable Drugs Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Peptide-based Injectable Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Generic Drug
5.3 Market Segment by Type
5.3.1 World Peptide-based Injectable Drugs Market Size by Type (2018-2023)
5.3.2 World Peptide-based Injectable Drugs Market Size by Type (2024-2029)
5.3.3 World Peptide-based Injectable Drugs Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peptide-based Injectable Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Cancer
6.2.2 Metabolic Disorders
6.2.3 Central Nervous System
6.2.4 Other
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World Peptide-based Injectable Drugs Market Size by Application (2018-2023)
6.3.2 World Peptide-based Injectable Drugs Market Size by Application (2024-2029)
6.3.3 World Peptide-based Injectable Drugs Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Sanofi
7.1.1 Sanofi Details
7.1.2 Sanofi Major Business
7.1.3 Sanofi Peptide-based Injectable Drugs Product and Services
7.1.4 Sanofi Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Sanofi Recent Developments/Updates
7.1.6 Sanofi Competitive Strengths & Weaknesses
7.2 Teva
7.2.1 Teva Details
7.2.2 Teva Major Business
7.2.3 Teva Peptide-based Injectable Drugs Product and Services
7.2.4 Teva Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Teva Recent Developments/Updates
7.2.6 Teva Competitive Strengths & Weaknesses
7.3 Novo Nordisk
7.3.1 Novo Nordisk Details
7.3.2 Novo Nordisk Major Business
7.3.3 Novo Nordisk Peptide-based Injectable Drugs Product and Services
7.3.4 Novo Nordisk Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Novo Nordisk Recent Developments/Updates
7.3.6 Novo Nordisk Competitive Strengths & Weaknesses
7.4 Takeda
7.4.1 Takeda Details
7.4.2 Takeda Major Business
7.4.3 Takeda Peptide-based Injectable Drugs Product and Services
7.4.4 Takeda Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Takeda Recent Developments/Updates
7.4.6 Takeda Competitive Strengths & Weaknesses
7.5 Eli Lilly
7.5.1 Eli Lilly Details
7.5.2 Eli Lilly Major Business
7.5.3 Eli Lilly Peptide-based Injectable Drugs Product and Services
7.5.4 Eli Lilly Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Eli Lilly Recent Developments/Updates
7.5.6 Eli Lilly Competitive Strengths & Weaknesses
7.6 AstraZeneca
7.6.1 AstraZeneca Details
7.6.2 AstraZeneca Major Business
7.6.3 AstraZeneca Peptide-based Injectable Drugs Product and Services
7.6.4 AstraZeneca Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 AstraZeneca Recent Developments/Updates
7.6.6 AstraZeneca Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Peptide-based Injectable Drugs Product and Services
7.7.4 Novartis Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 AbbVie
7.8.1 AbbVie Details
7.8.2 AbbVie Major Business
7.8.3 AbbVie Peptide-based Injectable Drugs Product and Services
7.8.4 AbbVie Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 AbbVie Recent Developments/Updates
7.8.6 AbbVie Competitive Strengths & Weaknesses
7.9 Ipsen
7.9.1 Ipsen Details
7.9.2 Ipsen Major Business
7.9.3 Ipsen Peptide-based Injectable Drugs Product and Services
7.9.4 Ipsen Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Ipsen Recent Developments/Updates
7.9.6 Ipsen Competitive Strengths & Weaknesses
7.10 Ferring
7.10.1 Ferring Details
7.10.2 Ferring Major Business
7.10.3 Ferring Peptide-based Injectable Drugs Product and Services
7.10.4 Ferring Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Ferring Recent Developments/Updates
7.10.6 Ferring Competitive Strengths & Weaknesses
7.11 Merck
7.11.1 Merck Details
7.11.2 Merck Major Business
7.11.3 Merck Peptide-based Injectable Drugs Product and Services
7.11.4 Merck Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Merck Recent Developments/Updates
7.11.6 Merck Competitive Strengths & Weaknesses
7.12 The Medicines
7.12.1 The Medicines Details
7.12.2 The Medicines Major Business
7.12.3 The Medicines Peptide-based Injectable Drugs Product and Services
7.12.4 The Medicines Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 The Medicines Recent Developments/Updates
7.12.6 The Medicines Competitive Strengths & Weaknesses
7.13 Roche
7.13.1 Roche Details
7.13.2 Roche Major Business
7.13.3 Roche Peptide-based Injectable Drugs Product and Services
7.13.4 Roche Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Roche Recent Developments/Updates
7.13.6 Roche Competitive Strengths & Weaknesses
7.14 J & J
7.14.1 J & J Details
7.14.2 J & J Major Business
7.14.3 J & J Peptide-based Injectable Drugs Product and Services
7.14.4 J & J Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 J & J Recent Developments/Updates
7.14.6 J & J Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peptide-based Injectable Drugs Industry Chain
8.2 Peptide-based Injectable Drugs Upstream Analysis
8.3 Peptide-based Injectable Drugs Midstream Analysis
8.4 Peptide-based Injectable Drugs Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Peptide-based Injectable Drugs Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Peptide-based Injectable Drugs Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Peptide-based Injectable Drugs Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Peptide-based Injectable Drugs Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Peptide-based Injectable Drugs Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide-based Injectable Drugs Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Peptide-based Injectable Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Peptide-based Injectable Drugs Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Peptide-based Injectable Drugs Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Peptide-based Injectable Drugs Players in 2022
Table 12. World Peptide-based Injectable Drugs Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Peptide-based Injectable Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Peptide-based Injectable Drugs Player
Table 15. Peptide-based Injectable Drugs Market: Company Product Type Footprint
Table 16. Peptide-based Injectable Drugs Market: Company Product Application Footprint
Table 17. Peptide-based Injectable Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Peptide-based Injectable Drugs Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Peptide-based Injectable Drugs Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Peptide-based Injectable Drugs Revenue Market Share (2018-2023)
Table 23. China Based Peptide-based Injectable Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Peptide-based Injectable Drugs Revenue Market Share (2018-2023)
Table 26. Rest of World Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Peptide-based Injectable Drugs Revenue Market Share (2018-2023)
Table 29. World Peptide-based Injectable Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Peptide-based Injectable Drugs Market Size by Type (2018-2023) & (USD Million)
Table 31. World Peptide-based Injectable Drugs Market Size by Type (2024-2029) & (USD Million)
Table 32. World Peptide-based Injectable Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Peptide-based Injectable Drugs Market Size by Application (2018-2023) & (USD Million)
Table 34. World Peptide-based Injectable Drugs Market Size by Application (2024-2029) & (USD Million)
Table 35. Sanofi Basic Information, Area Served and Competitors
Table 36. Sanofi Major Business
Table 37. Sanofi Peptide-based Injectable Drugs Product and Services
Table 38. Sanofi Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Sanofi Recent Developments/Updates
Table 40. Sanofi Competitive Strengths & Weaknesses
Table 41. Teva Basic Information, Area Served and Competitors
Table 42. Teva Major Business
Table 43. Teva Peptide-based Injectable Drugs Product and Services
Table 44. Teva Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Teva Recent Developments/Updates
Table 46. Teva Competitive Strengths & Weaknesses
Table 47. Novo Nordisk Basic Information, Area Served and Competitors
Table 48. Novo Nordisk Major Business
Table 49. Novo Nordisk Peptide-based Injectable Drugs Product and Services
Table 50. Novo Nordisk Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Novo Nordisk Recent Developments/Updates
Table 52. Novo Nordisk Competitive Strengths & Weaknesses
Table 53. Takeda Basic Information, Area Served and Competitors
Table 54. Takeda Major Business
Table 55. Takeda Peptide-based Injectable Drugs Product and Services
Table 56. Takeda Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Takeda Recent Developments/Updates
Table 58. Takeda Competitive Strengths & Weaknesses
Table 59. Eli Lilly Basic Information, Area Served and Competitors
Table 60. Eli Lilly Major Business
Table 61. Eli Lilly Peptide-based Injectable Drugs Product and Services
Table 62. Eli Lilly Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Eli Lilly Recent Developments/Updates
Table 64. Eli Lilly Competitive Strengths & Weaknesses
Table 65. AstraZeneca Basic Information, Area Served and Competitors
Table 66. AstraZeneca Major Business
Table 67. AstraZeneca Peptide-based Injectable Drugs Product and Services
Table 68. AstraZeneca Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. AstraZeneca Recent Developments/Updates
Table 70. AstraZeneca Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Area Served and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Peptide-based Injectable Drugs Product and Services
Table 74. Novartis Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. AbbVie Basic Information, Area Served and Competitors
Table 78. AbbVie Major Business
Table 79. AbbVie Peptide-based Injectable Drugs Product and Services
Table 80. AbbVie Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. AbbVie Recent Developments/Updates
Table 82. AbbVie Competitive Strengths & Weaknesses
Table 83. Ipsen Basic Information, Area Served and Competitors
Table 84. Ipsen Major Business
Table 85. Ipsen Peptide-based Injectable Drugs Product and Services
Table 86. Ipsen Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Ipsen Recent Developments/Updates
Table 88. Ipsen Competitive Strengths & Weaknesses
Table 89. Ferring Basic Information, Area Served and Competitors
Table 90. Ferring Major Business
Table 91. Ferring Peptide-based Injectable Drugs Product and Services
Table 92. Ferring Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Ferring Recent Developments/Updates
Table 94. Ferring Competitive Strengths & Weaknesses
Table 95. Merck Basic Information, Area Served and Competitors
Table 96. Merck Major Business
Table 97. Merck Peptide-based Injectable Drugs Product and Services
Table 98. Merck Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Merck Recent Developments/Updates
Table 100. Merck Competitive Strengths & Weaknesses
Table 101. The Medicines Basic Information, Area Served and Competitors
Table 102. The Medicines Major Business
Table 103. The Medicines Peptide-based Injectable Drugs Product and Services
Table 104. The Medicines Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. The Medicines Recent Developments/Updates
Table 106. The Medicines Competitive Strengths & Weaknesses
Table 107. Roche Basic Information, Area Served and Competitors
Table 108. Roche Major Business
Table 109. Roche Peptide-based Injectable Drugs Product and Services
Table 110. Roche Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Roche Recent Developments/Updates
Table 112. J & J Basic Information, Area Served and Competitors
Table 113. J & J Major Business
Table 114. J & J Peptide-based Injectable Drugs Product and Services
Table 115. J & J Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 116. Global Key Players of Peptide-based Injectable Drugs Upstream (Raw Materials)
Table 117. Peptide-based Injectable Drugs Typical Customers
Table 1. World Peptide-based Injectable Drugs Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Peptide-based Injectable Drugs Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Peptide-based Injectable Drugs Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Peptide-based Injectable Drugs Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Peptide-based Injectable Drugs Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide-based Injectable Drugs Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Peptide-based Injectable Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Peptide-based Injectable Drugs Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Peptide-based Injectable Drugs Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Peptide-based Injectable Drugs Players in 2022
Table 12. World Peptide-based Injectable Drugs Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Peptide-based Injectable Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Peptide-based Injectable Drugs Player
Table 15. Peptide-based Injectable Drugs Market: Company Product Type Footprint
Table 16. Peptide-based Injectable Drugs Market: Company Product Application Footprint
Table 17. Peptide-based Injectable Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Peptide-based Injectable Drugs Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Peptide-based Injectable Drugs Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Peptide-based Injectable Drugs Revenue Market Share (2018-2023)
Table 23. China Based Peptide-based Injectable Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Peptide-based Injectable Drugs Revenue Market Share (2018-2023)
Table 26. Rest of World Based Peptide-based Injectable Drugs Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Peptide-based Injectable Drugs Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Peptide-based Injectable Drugs Revenue Market Share (2018-2023)
Table 29. World Peptide-based Injectable Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Peptide-based Injectable Drugs Market Size by Type (2018-2023) & (USD Million)
Table 31. World Peptide-based Injectable Drugs Market Size by Type (2024-2029) & (USD Million)
Table 32. World Peptide-based Injectable Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Peptide-based Injectable Drugs Market Size by Application (2018-2023) & (USD Million)
Table 34. World Peptide-based Injectable Drugs Market Size by Application (2024-2029) & (USD Million)
Table 35. Sanofi Basic Information, Area Served and Competitors
Table 36. Sanofi Major Business
Table 37. Sanofi Peptide-based Injectable Drugs Product and Services
Table 38. Sanofi Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Sanofi Recent Developments/Updates
Table 40. Sanofi Competitive Strengths & Weaknesses
Table 41. Teva Basic Information, Area Served and Competitors
Table 42. Teva Major Business
Table 43. Teva Peptide-based Injectable Drugs Product and Services
Table 44. Teva Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Teva Recent Developments/Updates
Table 46. Teva Competitive Strengths & Weaknesses
Table 47. Novo Nordisk Basic Information, Area Served and Competitors
Table 48. Novo Nordisk Major Business
Table 49. Novo Nordisk Peptide-based Injectable Drugs Product and Services
Table 50. Novo Nordisk Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Novo Nordisk Recent Developments/Updates
Table 52. Novo Nordisk Competitive Strengths & Weaknesses
Table 53. Takeda Basic Information, Area Served and Competitors
Table 54. Takeda Major Business
Table 55. Takeda Peptide-based Injectable Drugs Product and Services
Table 56. Takeda Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Takeda Recent Developments/Updates
Table 58. Takeda Competitive Strengths & Weaknesses
Table 59. Eli Lilly Basic Information, Area Served and Competitors
Table 60. Eli Lilly Major Business
Table 61. Eli Lilly Peptide-based Injectable Drugs Product and Services
Table 62. Eli Lilly Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Eli Lilly Recent Developments/Updates
Table 64. Eli Lilly Competitive Strengths & Weaknesses
Table 65. AstraZeneca Basic Information, Area Served and Competitors
Table 66. AstraZeneca Major Business
Table 67. AstraZeneca Peptide-based Injectable Drugs Product and Services
Table 68. AstraZeneca Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. AstraZeneca Recent Developments/Updates
Table 70. AstraZeneca Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Area Served and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Peptide-based Injectable Drugs Product and Services
Table 74. Novartis Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. AbbVie Basic Information, Area Served and Competitors
Table 78. AbbVie Major Business
Table 79. AbbVie Peptide-based Injectable Drugs Product and Services
Table 80. AbbVie Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. AbbVie Recent Developments/Updates
Table 82. AbbVie Competitive Strengths & Weaknesses
Table 83. Ipsen Basic Information, Area Served and Competitors
Table 84. Ipsen Major Business
Table 85. Ipsen Peptide-based Injectable Drugs Product and Services
Table 86. Ipsen Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Ipsen Recent Developments/Updates
Table 88. Ipsen Competitive Strengths & Weaknesses
Table 89. Ferring Basic Information, Area Served and Competitors
Table 90. Ferring Major Business
Table 91. Ferring Peptide-based Injectable Drugs Product and Services
Table 92. Ferring Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Ferring Recent Developments/Updates
Table 94. Ferring Competitive Strengths & Weaknesses
Table 95. Merck Basic Information, Area Served and Competitors
Table 96. Merck Major Business
Table 97. Merck Peptide-based Injectable Drugs Product and Services
Table 98. Merck Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Merck Recent Developments/Updates
Table 100. Merck Competitive Strengths & Weaknesses
Table 101. The Medicines Basic Information, Area Served and Competitors
Table 102. The Medicines Major Business
Table 103. The Medicines Peptide-based Injectable Drugs Product and Services
Table 104. The Medicines Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. The Medicines Recent Developments/Updates
Table 106. The Medicines Competitive Strengths & Weaknesses
Table 107. Roche Basic Information, Area Served and Competitors
Table 108. Roche Major Business
Table 109. Roche Peptide-based Injectable Drugs Product and Services
Table 110. Roche Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Roche Recent Developments/Updates
Table 112. J & J Basic Information, Area Served and Competitors
Table 113. J & J Major Business
Table 114. J & J Peptide-based Injectable Drugs Product and Services
Table 115. J & J Peptide-based Injectable Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 116. Global Key Players of Peptide-based Injectable Drugs Upstream (Raw Materials)
Table 117. Peptide-based Injectable Drugs Typical Customers
LIST OF FIGURES
Figure 1. Peptide-based Injectable Drugs Picture
Figure 2. World Peptide-based Injectable Drugs Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Peptide-based Injectable Drugs Total Market Size (2018-2029) & (USD Million)
Figure 4. World Peptide-based Injectable Drugs Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Peptide-based Injectable Drugs Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 13. Peptide-based Injectable Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 16. World Peptide-based Injectable Drugs Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 18. China Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. India Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Peptide-based Injectable Drugs by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide-based Injectable Drugs Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide-based Injectable Drugs Markets in 2022
Figure 27. United States VS China: Peptide-based Injectable Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Peptide-based Injectable Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Peptide-based Injectable Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Peptide-based Injectable Drugs Market Size Market Share by Type in 2022
Figure 31. Brand
Figure 32. Generic Drug
Figure 33. World Peptide-based Injectable Drugs Market Size Market Share by Type (2018-2029)
Figure 34. World Peptide-based Injectable Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Peptide-based Injectable Drugs Market Size Market Share by Application in 2022
Figure 36. Cancer
Figure 37. Metabolic Disorders
Figure 38. Central Nervous System
Figure 39. Other
Figure 40. Peptide-based Injectable Drugs Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
Figure 1. Peptide-based Injectable Drugs Picture
Figure 2. World Peptide-based Injectable Drugs Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Peptide-based Injectable Drugs Total Market Size (2018-2029) & (USD Million)
Figure 4. World Peptide-based Injectable Drugs Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Peptide-based Injectable Drugs Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Peptide-based Injectable Drugs Revenue (2018-2029) & (USD Million)
Figure 13. Peptide-based Injectable Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 16. World Peptide-based Injectable Drugs Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 18. China Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. India Peptide-based Injectable Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Peptide-based Injectable Drugs by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide-based Injectable Drugs Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide-based Injectable Drugs Markets in 2022
Figure 27. United States VS China: Peptide-based Injectable Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Peptide-based Injectable Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Peptide-based Injectable Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Peptide-based Injectable Drugs Market Size Market Share by Type in 2022
Figure 31. Brand
Figure 32. Generic Drug
Figure 33. World Peptide-based Injectable Drugs Market Size Market Share by Type (2018-2029)
Figure 34. World Peptide-based Injectable Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Peptide-based Injectable Drugs Market Size Market Share by Application in 2022
Figure 36. Cancer
Figure 37. Metabolic Disorders
Figure 38. Central Nervous System
Figure 39. Other
Figure 40. Peptide-based Injectable Drugs Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
